2014 Oncology Nursing Drug Handbook

Written especially for nurses caring for patients with cancer, the 2014 Oncology Nursing Drug Handbook uniquely expresses drug therapy in terms of the nursing process: nursing diagnoses, etiologies of toxicities, and key points for nursing assessment, intervention, and evaluation. Updated annually, this essential reference provides valuable information on effective symptom management, patient education, and chemotherapy administration.

Completely revised and updated, the 2014 Oncology Nursing Drug Handbook includes:

* New chapter on Chemobiotherapy for Noncancer Diseases
* Specific drugs described in terms of their mechanism of action, metabolism, drug interactions, laboratory effects/interference, and special considerations
* The most important and common drug side effects
* Greater discussion of fundamentals of malignant transformation, new molecular targets, and drugs in the pipeline

New drug entries include: enzalutamide, omacetaxine (Synribo), tbo-filgrastim (Netroval), ado-trastuzumab emtansine, aflibercept, bosutinib, cabozantinib, carfilzomib, dabrafenib, pomalidomide, ponatinib, regorafenib, trametinib, abatacept (Orencia), adalimumab (Humira), certolizumab pegol (CIMZA), etanercept (Enbrel), golimumab (Simponi), infliximab (Remicade), tocilizumab (Actemra), and tofacitinib (Xeljanz).